Certified by Founder Lodge
T. Rowe Price
United States - Baltimore, Maryland
INVESTOR
1 Disclosed Funding Rounds $223,000,000
34 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
T. Rowe Price is an asset management firm focused on delivering global investment management excellence and retirement services that investors can rely on—now, and over the long term.
Head
| Company | Date | Round | Raised |
|---|---|---|---|
 Sortera Technologies, Inc. |
August, 31 ,2023 | Series C | $30,500,000 |
 Cleerly |
July, 25 ,2022 | Series C | $223,000,000 |
 Flexe |
July, 07 ,2022 | Series D | $119,000,000 |
 Generate:Biomedicines |
September, 18 ,2023 | Series C | $273,000,000 |
 CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
 Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
 Tessera Therapeutics |
April, 19 ,2022 | Series C | $300,000,000 |
 Stash |
October, 16 ,2023 | Unknown | $40,000,000 |
 Saluda Medical |
April, 17 ,2023 | Unknown | $150,000,000 |
 Apiture |
November, 15 ,2023 | Unknown | $10,000,000 |
 KoBold Metals |
June, 21 ,2023 | Unknown | $195,000,000 |
 RefleXion Medical |
November, 17 ,2023 | Unknown | $105,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
 Genesis Therapeutics |
August, 22 ,2023 | Series B | $200,000,000 |
 Lambda |
February, 16 ,2024 | Series C | $320,000,000 |
| Sortera Technologies, Inc. |
August, 31 ,2023 | Series C | $30,500,000 |
 Sionna Therapeutics |
March, 07 ,2024 | Series C | $182,000,000 |
| Generate:Biomedicines |
September, 18 ,2023 | Series C | $273,000,000 |
 Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
| Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
 Kardium Inc. |
June, 12 ,2024 | Unknown | $104,000,000 |
| Stash |
October, 16 ,2023 | Unknown | $40,000,000 |
 Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
| Apiture |
November, 15 ,2023 | Unknown | $10,000,000 |
| RefleXion Medical |
November, 17 ,2023 | Unknown | $105,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| Lambda |
February, 16 ,2024 | Series C | $320,000,000 |
| Sionna Therapeutics |
March, 07 ,2024 | Series C | $182,000,000 |
| Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
| Kardium Inc. |
June, 12 ,2024 | Unknown | $104,000,000 |
| Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
 Form Energy |
October, 11 ,2024 | Series F | $405,000,000 |
 Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
Founderpath
Truework
Finix
Farther
TeamApt Inc.
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
